Seborrhoeic dermatitis and sebopsoriasis developing in patients on dupilumab: Two case reports

Cutaneous adverse events to dupilumab can be varied; this necessitates keeping a broad differential diagnosis to identify seemingly paradoxical reactions. It may be possible to treat the adverse event concurrently without stopping dupilumab.

Detalles Bibliográficos
Autores principales: Al‐Janabi, Ali, Marsland, Alexander M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455398/
https://www.ncbi.nlm.nih.gov/pubmed/32884774
http://dx.doi.org/10.1002/ccr3.2871
Descripción
Sumario:Cutaneous adverse events to dupilumab can be varied; this necessitates keeping a broad differential diagnosis to identify seemingly paradoxical reactions. It may be possible to treat the adverse event concurrently without stopping dupilumab.

Ejemplares similares